Review: recent advances and future development of metal complexes as anticancer agents

Jia, Pengpeng; Ouyang, Ruizhuo; Cao, Penghui; Tong, Xiao; Zhou, Xizhao; Tian, Lei; Zhao, Yuefeng; Guo, Ning; Chang, Haizhou; Miao, Yuqing; Zhou, Shuang

doi:10.1080/00958972.2017.1349313

Cited by 107 publications

(69 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[35] After the breakthrough of cisplatin, the second-and thirdgeneration cisplatin analogues, carboplatin (cis-diammine(1,1cyclobutanecarboxylato) platinum(II)) and oxaliplatin (1R,2Rdiaminocyclohexane oxalatoplatinum(II)) were developed to reduce toxicity to tissues or organs, improve chemical stability and expand the scope of activity of these platinum compounds. [37,38] Both agents successfully passed phase III clinical trials and are now FDA-approved anti-cancer drugs. Likewise, they react with DNA forming platinum-induced intraand inter-strand crosslinks and were proven effective in various cancers with reduced toxicity compared to cisplatin.…”

Section: Platinum Metal-based Complexesmentioning

confidence: 99%

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy

2020

View full text Add to dashboard Cite

Platinum drugs are heavily used first-line chemotherapeutic agents for many solid tumours and have stimulated substantial interest in the biological activity of DNA-binding metal complexes. These complexes generate DNA lesions which trigger the activation of DNA damage response (DDR) pathways that are essential to maintain genomic integrity. Cancer cells exploit this intrinsic DNA repair network to counteract many types of chemotherapies. Now, advances in the molecular biology of cancer has paved the way for the combination of DDR inhibitors such as poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) and agents that induce high levels of DNA replication stress or single-strand break damage for synergistic cancer cell killing. In this review, we summarise early-stage, preclinical and clinical findings exploring platinum and emerging ruthenium anti-cancer complexes alongside PARPi in combination therapy for cancer and also describe emerging work on the ability of ruthenium and gold complexes to directly inhibit PARP activity.

show abstract

Section: Platinum Metal-based Complexesmentioning

confidence: 99%

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy

2020

View full text Add to dashboard Cite

show abstract

“…To overcome these difficulties, new platinum complexes have been devised and their anti-tumour properties investigated. 11,12,38,63 Although thousands of compounds have been prepared and tested, very few are approved for clinical use (Figure 8). 38…”

Section: Platinummentioning

confidence: 99%

“…Advances and future perspectives of metal complexes as anticancer agents 63 Update from drug design perspective of metal complexes in cancer therapy 11…”

Section: Cancermentioning

confidence: 99%

An overview on ligands of therapeutically interest

Martin¹,

Alés²,

Asuero³

2018

PPIJ

View full text Add to dashboard Cite

The principles governing metal-ligand complex stability and specificity depend on the properties of both the metal and the chelating agent. The exploration of coordination chemistry offers the real prospects of providing new understanding of intractable diseases and of devising novel therapeutics and diagnosis agents. Refinement in the approach to chelator design has come with a more subtle understanding of binding kinetics, catalytic mechanisms and donor interactions. Ligands that effectively bind metal ions and also include specific features to enhance targeting, reporting, and overall efficacy are driving innovation in areas of disease, diagnosis and therapy. In this contribution the topics of bioinorganic medicinal chemistry, chelating agents in the treatment of metallic ion overload in the body, and expanding the notion of chelating agent in medicine are successively dealt with, paying then attention to platinum, gold, iron, copper and aluminium ion metal complexes having medicinal interest. A tabular summary containing selected applications of ligands and complexes of therapeutic interest is also shown to including the most relevant and current bibliography. A number of papers concerning miscellaneous topics based on selected key words are also tabulated. Metal chelation principles offer wide new opportunities in the drug design field in addition to the classical answer of metal sequestration or elimination.

show abstract

“…The role of metal complexes in medicinal chemistry is well‐documented. In metal complexes, the ligands bearing oxygen, and nitrogen donor atoms carry unique importance due to their binding properties with metal atoms . The presence of amino (‐NH 2 ) and carboxylic (‐COO ¯ ) group in an amino acid also serve as a source of N/O donating atoms in the formation of metal complexes.…”

Section: Introductionmentioning

confidence: 99%

8‐Hydroxyquinoline‐Methionine Mixed Ligands Metal Complexes: Preparation and Their Antioxidant Activity

et al. 2019

View full text Add to dashboard Cite

The purpose of this investigation is to synthesize mixed ligand complexes of first, second, and third row transition metals including Cr (III), Mn (II), Fe (III), Co (II), Ni (II), Cu (II), Zn (II), Cd (II) and Pb (II) with L 1 = 8-hydroxyquinoline and L 2 = DLmethionine. Newly synthesized metal complexes have been characterized by UV-Visible, IR, mass spectrometry and microanalytical techniques such as conductance measurement, elemental analysis, and melting point. Synthetic mixed complexes were also screened for antioxidant activity.

show abstract

Review: recent advances and future development of metal complexes as anticancer agents

Cited by 107 publications

References 98 publications

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy

An overview on ligands of therapeutically interest

8‐Hydroxyquinoline‐Methionine Mixed Ligands Metal Complexes: Preparation and Their Antioxidant Activity

Contact Info

Product

Resources

About